News

2021

Click Therapeutics

April 07, 2021—Click Therapeutics Expands its Leadership with Executive and Board Appointments

View PDF 

 

Icosavax

April 7, 2021—Icosavax Closes $100 Million Series B Financing to Advance Bivalent RSV/hMPV Vaccine Candidate Into Clinical Trials.

View PDF 

 

Evidation

March 25, 2021—Evidation Raises $153M to Scale Virtual Health Capabilities of Achievement™ Platform.

View PDF 

 

Lava Therapeutics

March 21, 2021—LAVA Therapeutics Announces Pricing of Initial Public Offering .

View PDF 

 

Amathus

March 17, 2021—Amathus Therapeutics signs strategic collaboration with Merck to Develop Treatments for Neurodegenerative Diseases.

View PDF 

 

Lava Therapeutics

March 15, 2021—LAVA Therapeutics Appoints Edward F. Smith as Chief Financial Officer.

View PDF 

 

Medisafe

February 25, 2021—Medisafe Secures $30M in Series C Funding led by Sanofi Ventures and ALIVE Israel HealthTech Fund to Build Future Model of Patient Support.

View PDF 

 

Click Therapeutics

February 24, 2021—Otsuka and Click Therapeutics Initiate First-of-its-Kind Fully Remote Clinical Trial Using Digital Therapeutics as Adjunctive Therapy in Adults With Major Depressive Disorder.

View PDF 

 

Lava Therapeutics

February 22, 2021—Lava Therapeutics appoints Dr. Kapil Dhingra as Chairman of the Board of Directors in Advance of Lead Program Entering the Clinic.

View PDF 

 

i2O Therapeutics

February 10, 2021—i2O Therapeutics, developers of a platform for oral delivery of traditionally injectable biological drugs, announced today a research collaboration with Sanofi to investigate the oral delivery of Sanofi's Nanobody®-based medicines, which are currently administered through intravenous or subcutaneous injections.

View PDF 

 

2020

Minervax

December 15, 2020—Minervax raises upsized EUR 47.4M Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials

View PDF 

 

NodThera

December 15, 2020—NodThera Appoints Chief Medical Officer and Chief Financial Officer

View PDF 

 

Icosavax

October 30, 2020—Icosavax Launches COVID-19 Vaccine Program with Preclinical Data and $16.5 Million in New Funding

View PDF 

 

Q32 Bio

October 29, 2020—Q32 Bio Closes $60 Million Series B Financing, Advances to Clinical Stage Research in Therapeutics Designed to Restore Immune Homeostasis

View PDF 

  

Lava Therapeutics

September 17, 2020—Lava Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs

View PDF 

  

Escient Pharmaceuticals

September 14, 2020—Escient Pharmaceuticals Raises $77.5 Million Series B Round and Initiates a Phase 1/1b Clinical Trial of EP547, a MRGPR-targeted Therapy to Treat Cholestatic and Uremic Pruritis

View PDF 

 

Click Therapeutics

September 11, 2020—Click Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia

View PDF 

 

Kymera Therapeutics

August 21, 2020—Kymera Therapeutics Announces Pricing of Upsized Initial Public Offering

View PDF 

 

Science 37

August 20, 2020—Science 37 Raises $40 Million to Extend its Leadership in the Decentralized Clinical Trial Market

View PDF 

 

Fulcrum Therapeutics

July 21, 2020—MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies

View PDF 

 

Curisium

July 20, 2020—HealthVerity Acquires Curisium to Enhance Data Exchange for Drug Rebate Processing and Contract Management

View PDF 

 

Kymera Therapeutics

July 9, 2020—Kymera Therapeutics and Sanofi Enter into Strategic Partnership to Advance Novel Protein Degrader Therapies to Patients

View PDF 

 

Evidation

July 1, 2020—Evidation Raises $45 Million Series D, Hires CCO To Accelerate Commercial Momentum and Expand Into Virtual Health

View PDF 

 

Fulcrum Therapeutics

June 10, 2020—Fulcrum Therapeutics Completes $68.5 Million Private Placement

View PDF 

 

Evidation

June 5, 2020— Evidation Health and BARDA Partner on Early Warning System for COVID-19

View PDF 

 

NodThera

June 3, 2020— NodThera a clinical stage biotechnology company developing a new class of medicines that inhibit the NLRP3 inflammasome to treat diseases driven by chronic inflammation, today announced that it has secured $55 million (£44
million) in a Series B financing

View PDF 

 

Q32 Bio

May 27, 2020—Q32 Bio Launches to Develop Novel Therapeutics Targeting Regulators of Innate and Adaptive Immunity

View PDF 

 

i2O Therapeutics 

April 9, 2020—i2O Therapeutics, an innovative biotech company developing a platform for oral delivery of traditionally injectable biological drugs, announced today it has raised a $4 million seed funding round led by Sanofi Ventures and JDRF T1D Fund.

View PDF 

 

2019

 

 

Aetion

November 19, 2019 - Sanofi and Aetion launch enterprise-wide collaboration to advance regulatory submissions using real-world evidence 

View PDF 

 

Yumanity Therapeutics 

October 7, 2019 -Yumanity Therapeutics Initiates Phase 1 Clinical Trial of Lead Candidate YTX-7739 for the Treatment of Parkinson’s Disease 

View PDF 

 

Icosavax 

October 3, 2019 -Icosavax Launches with $51 Million Series A Financing to Advance Computationally Designed VLP Vaccines

View PDF 

 

Click Therapeutics 

September 6, 2019 -Click Therapeutics Announces Appointment of Top Ranked Healthcare Research Analyst Ross J. Muken as Chief Financial Officer

View PDF 

 

Veralox Therapeutics 

September 5, 2019 - Sanofi Ventures co-leads investment in Veralox Therapeutics to enable further develop first-in-class 12-LOX inhibitors for Heparin-Induced Thrombocytopenia and Thrombosis, Type 1 Diabetes, and other indications

View PDF 

 

Yumanity Therapeutics 

July 10, 2019 - Yumanity Therapeutics Appoints Richard Peters, M.D., Ph.D., as Chief Executive Officer

View PDF 

 

Ovid Therapeutics 

June 27, 2019 - Ovid Therapeutics Initiates Pivotal Phase 3 Clinical Trial in Angelman Syndrome;
Multiple Data Readouts Across Rare Neurological Disease Pipeline Expected in 2H 2019 and Early 2020

View PDF 

 

Omada Health

June 26, 2019 -Omada Health Raises $73 Million to Accelerate Program Expansion
Digital Care Leader’s Integrated Program Supports Individuals Dealing with Chronic
Disease, Mental Health Issues

View PDF

 

Kymera Therapeutics

May 15, 2019 -Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases.

View PDF

 

Inozyme Pharma

April 10 2019 - Inozyme Pharma, a biotechnology company developing novel medicines to treat rare, debilitating, and life-threatening mineralization disorders, today announced that the Company raised $67 million in a Series A2 financing led by Pivotal bioVenture Partners and Sofinnova Investments. Cross-over investors, including RA Capital Management, Cowen Healthcare Investments, and Rock Springs Capital, as well as the Company’s previous investors, Longitude Capital, NEA, Novo Holdings, and Sanofi Ventures, also joined this round.

View PDF

 

Aetion

February 5 2019 - Aetion, the health care technology company that delivers the real-world analytics and evidence platform needed to engage in value-based care, announced today a $27 Million Strategic Investment backed by Global Health Care Leaders 

View PDF

 

Navitor Pharmaceuticals

January 24 2019 - Navitor Pharmaceuticals Commences Phase 1 Clinical Evaluation of NV-5138, a Novel mTORC1 Activator in Patients with Treatment-Resistant Depression

View PDF

 

Click Therapeutics

January 3 2019 - Click Therapeutics, Inc. and Otsuka America, Inc., announce today that the companies have signed a collaboration agreement to develop and commercialize a prescription digital therapeutic for treatment of Major Depressive Disorder

View PDF